New Data Showed Cimzia R Provided Rapid And Sustained Clinical Response, And Reinforces Need For Rapid-acting Treatments For RA
UCB today announced data that showed rapid and sustained improvements in symptoms of RA, as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with certolizumab pegol, together with methotrexate (MTX), was sustained for two years. The results from an open-label extension study*** to RAPID 1*, were presented at the European League Against Rheumatism (EULAR) meeting in Copenhagen. New data from a post hoc** analysis, also presented at EULAR, showed the speed of developing a clinical response to treatment with 200 mg certolizumab pegol and MTX, is important in improving long-term outcomes for patients living with active RA.
A quarter of active rheumatoid arthritis (RA) patients receiving either 10mg (24.6%) or 15mg (28.1%) twice daily of the investigational oral JAK-3 (janus-associated kinase) inhibitor CP-690, 550 (CP) achieved ACR70* after 12 weeks, according to the results of a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. The primary outcome for the study was ACR20*, with 75.4% of patients achieving this measure at 12 weeks for both 10mg and 15mg doses. The study also showed that, comparatively, the ACR70* responses for adalimumab (ADA, a monoclonal antibody and anti-TNF) and placebo, were 3.
Medivation Completes Enrollment In Confirmatory, Pivotal Phase 3 'CONNECTION' Trial Of Dimebon In Patients With Alzheimer's Disease
Medivation, Inc. (Nasdaq: MDVN) announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer's disease. The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment target of 525 patients. More than 40 percent of the patients enrolled were in the United States. The six-month study is evaluating the effect of dimebon on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change plus caregiver interview (CIBIC-plus) -- the two endpoints have historically been accepted by the U.
Exercise Improves Functional And Psycological Ability And Reduces Steroid Need In Rheumatoid Arthritis
Undertaking a supervised exercise programme can have beneficial effects on functional status and physical function, reduce the need for daily corticosteroid and anti-inflammatory intake and improve levels of depression and anxiety in people with rheumatoid arthritis (RA), according to a new study presented at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark. A three-month programme, comprising moderate aerobic and strengthening exercises, conducted for 50-60 minutes three times per week, proved not only to be safe and beneficial both physically and in terms of quality of life for patients, but was also associated with a stabilising effect in disease activity measured by DAS28*.
Osteoarthritis is commonly diagnosed in the late and irreversible stages, when treatment can only be expected to decrease pain and slow progression of disease. Because osteoarthritis is a widespread problem in dogs, horses and humans, doctors and veterinarians need a precise way to diagnose the disease early and accurately. Now, University of Missouri researchers are investigating potential biomarkers in dogs for early diagnosis of osteoarthritis, which could help identify patients at increased risk of developing osteoarthritis. "By developing methods for earlier diagnosis of osteoarthritis, prevention or even curative treatment strategies to manage the disease become more realistic, " said James Cook, professor of veterinary medicine and surgery, and the William & Kathryn Allen Distinguished Professor in Orthopedic Surgery.
COPENHAGEN - The interleukin (IL)-6 receptor inhibitor tocilizumab (ActemraR) combined with methotrexate is more effective than methotrexate monotherapy in inhibiting the progression of structural joint damage in rheumatoid arthritis patients, according to results released at the 10th Annual Congress of the European League Against Rheumatism (EULAR) 2009. Joel Kremer, MD, Research Director at the Center for Rheumatology in Albany, New York, and co-workers examined the efficacy of adding tocilizumab to methotrexate in patients who had an inadequate response to methotrexate. The two-year, phase 3 LITHE (Tocilizumab Safety and The Prevention of Structural Joint Damage) trial was conducted in more than 1, 200 patients in 15 countries.